Fortress Biotech (FBIO) vs PMV Pharmaceuticals (PMVP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Fortress Biotech (FBIO) has outperformed PMV Pharmaceuticals (PMVP) over the past year, losing 26.6% versus a loss of 33.6%. Over five years, FBIO leads with a -95.5% price change compared with -96.2% for PMVP. PMV Pharmaceuticals is the larger company by market cap ($66.2 million vs $64.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | PMVP |
|---|---|---|
| Share price | $1.90 | $0.876 |
| Market cap | $64.11M | $66.17M |
| 1-day change | +7.34% | -33.13% |
| YTD return | -48.09% | -29.92% |
| 1-year return | -26.64% | -33.64% |
| 5-year return | -95.52% | -96.22% |
| P/E ratio (TTM) | 0.83 | — |
| EPS (TTM) | $2.30 | $-1.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $63.26M | — |
| Revenue growth (YoY) | +9.69% | — |
| Net income (latest FY) | $6.82M | $-77.74M |
| Gross margin | 66.92% | — |
| Operating margin | -111.00% | — |
| Net margin | 10.77% | — |
| 52-week high | $4.53 | $1.91 |
| 52-week low | $1.64 | $0.66 |
| Distance from 52-week high | -58.06% | -54.14% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +163.16% | +356.62% |
| Average volume | 281.49K | 787.50K |
| Shares outstanding | 33.74M | 75.53M |
| Employees | 78 | 54 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About PMV Pharmaceuticals
PMVP stock →PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 54 employees
FBIO vs PMVP FAQ
Which is bigger, Fortress Biotech or PMV Pharmaceuticals?
PMV Pharmaceuticals (PMVP) is larger, with a market capitalization of $66.17M compared with $64.11M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or PMVP?
FBIO returned -26.64% over the past 12 months, compared with -33.64% for PMVP (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and PMV Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.